Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors.

Atri Choksi¹, Matthew G Varga¹, Tiffany E Farmer¹, Vaia Florou², Drew Dill³, Kansas Krabbe⁴, David Tsao¹, Allen M Chen¹

¹BillionToOne, Inc., Menlo Park, CA, USA.

²University of Utah- Huntsman Cancer Institute, Salt Lake City, UT, USA.

³Baptist Cancer Center, Memphis, TN, USA.

⁴Ballad Health Cancer Care, Johnson City, TN, USA.

PubMed PMC DOI PDF

Abstract

Circulating tumor DNA (ctDNA), obtained serially during cancer treatment, can capture tumor burden trends to help interpret response and detect resistance to systemic therapy for patients with advanced disease. Traditionally, tumor-informed assays track somatic variants identified from an initial tumor biopsy and have demonstrated prognostic utility for early-stage disease. However, tumor-informed…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.